SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2007

 

OR

 

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to _______________

 

Commission File Number 0-16211

 

DENTSPLY International Inc.

_____________________________________________________________________

(Exact name of registrant as specified in its charter)

 

Delaware                                                                                                                                                39-1434669

_____________________________________________________________________________________

(State or other jurisdiction of                                                                                                           (I.R.S. Employer

incorporation or organization)                                                                                                         Identification No.)

 

221 West Philadelphia Street, York, PA                                                                                        17405-0872

_________________________________________________________________________________

(Address of principal executive offices)                                                                                          (Zip Code)

 

(717) 845-7511

(Registrant’s telephone number, including area code)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 

 

Yes

X

 

No

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes

X

 

No

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

X

 

Accelerated filer

 

 

Non-accelerated filer

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   

 

Yes

 

 

No

X

 

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: At August 1, 2007 DENTSPLY International Inc. (the “Company”) had 152,035,594 shares of Common Stock outstanding, with a par value of $.01 per share.

 

Page 1 of 34

 

 


DENTSPLY International Inc.

FORM 10-Q

 

For Quarter Ended June 30, 2007

 

INDEX

 

 

 

 

Page No.

 

PART I - FINANCIAL INFORMATION

 

Item 1 - Financial Statements (unaudited)

 

Consolidated Condensed Statements of Income

3

 

Consolidated Condensed Balance Sheets

4

 

Consolidated Condensed Statements of Cash Flows

5

Notes to Unaudited Interim Consolidated Condensed

 

Financial Statements

6

 

Item 2 - Management’s Discussion and Analysis of

 

Financial Condition and Results of Operations

20

 

Item 3 - Quantitative and Qualitative Disclosures

 

About Market Risk

31

 

 

Item 4 - Controls and Procedures

31

 

 

PART II - OTHER INFORMATION

 

 

Item 1 - Legal Proceedings

32

 

 

Item 1A - Risk Factors

33

 

 

Item 2 - Unregistered Sales of Securities and Use of Proceeds

33

 

 

Item 4 - Submission of Matters to a Vote of Security Holders

33

 

 

Item 6 - Exhibits

33

 

Signatures

34

 

 

 


DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES 

CONSOLIDATED CONDENSED STATEMENTS OF INCOME 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

Net sales

$       507,362

 

$      472,444

 

$     980,226

 

$  903,440

Cost of products sold

238,578

 

230,290

 

465,164

 

441,150

 

 

 

 

 

 

 

 

Gross profit

268,784

 

242,154

 

515,062

 

462,290

Selling, general and administrative expenses

172,084

 

152,926

 

336,161

 

298,357

Restructuring and other costs (Note 9)

3,207

 

2,636

 

4,197

 

7,333

 

 

 

 

 

 

 

 

Operating income

93,493

 

86,592

 

174,704

 

156,600

 

 

 

 

 

 

 

 

Other income and expenses:

 

 

 

 

 

 

 

Interest expense

5,209

 

8,765

 

9,665

 

16,145

Interest income

(6,995)

 

(9,204)

 

(13,496)

 

(17,271)

Other (income) expense, net

(347)

 

965

 

(557)

 

451

 

 

 

 

 

 

 

 

Income before income taxes

95,626

 

86,066

 

179,092

 

157,275

Provision for income taxes

30,193

 

26,750

 

55,187

 

47,955

 

 

 

 

 

 

 

 

Net income

$          65,433

 

$        59,316

 

$     123,905

 

$  109,320

 

 

 

 

 

 

 

 

Earnings per common share (Note 4):

 

 

 

 

 

 

 

-Basic

$              0.43

 

$             0.38

 

$            0.82

 

$         0.69

-Diluted

$              0.42

 

$             0.37

 

$            0.80

 

$         0.68

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash dividends declared per common share

$            0.040

 

$          0.035

 

$          0.080

 

$       0.070

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding (Note 4):

 

 

 

 

 

 

-Basic

152,000

 

156,814

 

152,016

 

157,402

-Diluted

154,873

 

159,834

 

154,723

 

160,446

 

 

 

 

 

 

 

 

See accompanying notes to Unaudited Interim Consolidated Condensed Financial Statements.

 

 

 

 

 

 


DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES

 

 

 

 

CONSOLIDATED CONDENSED BALANCE SHEETS

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

June 30,

 

December 31,

 

 

 

2007

 

2006

 

 

 

(in thousands)

Assets

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

 

$       69,433

 

$         65,064

 

Short-term investments

 

110,791

 

79

 

Accounts and notes receivable-trade, net (Note 1)

 

322,900

 

290,791

 

Inventories, net (Note 7)

 

249,864

 

232,441

 

Prepaid expenses and other current assets

 

116,757

 

129,816

 

 

 

 

 

 

 

Total Current Assets

 

869,745

 

718,191

 

 

 

 

 

 

 

Property, plant and equipment, net

 

333,949

 

329,616

 

Identifiable intangible assets, net

 

71,425

 

67,648

 

Goodwill, net

 

1,020,020

 

995,382

 

Other noncurrent assets, net

 

93,431

 

70,513

 

 

 

 

 

 

Total Assets

 

$  2,388,570

 

$  2,181,350

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Accounts payable

 

$       87,031

 

$         79,951

 

Accrued liabilities

 

171,543

 

181,196

 

Income taxes payable

 

27,397

 

47,292

 

Notes payable and current portion

 

 

 

 

 

of long-term debt

 

5,104

 

2,995

 

 

 

 

 

 

 

Total Current Liabilities

 

291,075

 

311,434

 

 

 

 

 

 

 

Long-term debt (Note 12)

 

397,124

 

367,161

 

Deferred income taxes

 

56,716

 

53,191

 

Other noncurrent liabilities

 

244,920

 

175,507

 

 

 

 

 

 

 

Total Liabilities

 

989,835

 

907,293

 

 

 

 

 

 

 

Minority interests in consolidated subsidiaries

 

249

 

222

 

 

 

 

 

 

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

Preferred stock, $.01 par value; .25 million

 

 

 

 

 

shares authorized; no shares issued

 

-

 

-

 

Common stock, $.01 par value; 200 million shares authorized;

 

 

 

 

 

162.8 million shares issued at June 30, 2007 and December 31, 2006 

1,628

 

1,628

 

Capital in excess of par value

 

167,766

 

168,135

 

Retained earnings

 

1,460,526

 

1,352,342

 

Accumulated other comprehensive income (Note 3)

 

101,858

 

79,914

 

Treasury stock, at cost, 10.8 million shares at June 30, 2007 and

 

 

 

 

 

11.0 million shares at December 31, 2006

 

(333,292)

 

(328,184)

 

 

 

 

 

 

 

Total Stockholders’ Equity

 

1,398,486

 

1,273,835

 

 

 

 

 

 

Total Liabilities and Stockholders’ Equity

 

$  2,388,570

 

$  2,181,350

 

 

 

 

 

 

See accompanying notes to Unaudited Interim Consolidated Condensed Financial Statements.

 

 

 

 


DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES

 

 

 

 

 

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended June 30,

 

 

 

2007

 

2006

 

 

 

(in thousands)

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

$         123,905

 

$        109,320

 

 

 

 

 

 

Adjustments to reconcile net income to net cash

 

 

 

 

 

provided by operating activities:

 

 

 

 

 

Depreciation

 

 

21,505

 

19,959

Amortization

 

 

3,847

 

3,438

Share-based compensation expense

 

 

7,124

 

8,476

Restructuring and other costs

 

 

4,197

 

7,333

Other, net

 

 

(5,504)

 

(55,858)

 

 

 

 

 

 

Net cash provided by operating activities

 

 

155,074

 

92,668

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(21,159)

 

(21,781)

Acquisitions of businesses, net of cash acquired

 

 

(26,223)

 

(6,448)

Expenditures for identifiable intangible assets

 

 

(3,003)

 

-

Purchases of short-term investments

 

 

(109,233)

 

(217,104)

Liquidations of short-term investments

 

 

67

 

31,777

Other, net

 

 

236

 

431

 

 

 

 

 

 

Net cash used in investing activities

 

 

(159,315)

 

(213,125)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

Payments on long-term borrowings

 

 

(117,161)

 

(42,102)

Net change in short-term borrowings

 

 

1,636

 

6,079

Cash paid for treasury stock

 

 

(44,222)

 

(146,918)

Cash dividends paid

 

 

(12,976)

 

(11,062)

Proceeds from long-term borrowings

 

 

149,548

 

114,065

Proceeds from exercise of stock options

 

 

26,312

 

21,212

Excess tax benefits from share-based compensation

 

 

3,659

 

4,933

 

 

 

 

 

 

Net cash provided by (used in) financing activities

 

 

6,796

 

(53,793)

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

1,814

 

22,963

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

4,369

 

(151,287)

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

 

65,064

 

433,984

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

 

$           69,433

 

$        282,697

 

 

 

 

 

 

See accompanying notes to Unaudited Interim Consolidated Condensed Financial Statements.

 

 

 

 


DENTSPLY International Inc.

 

NOTES TO UNAUDITED INTERIM CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

 

June 30, 2007

 

The accompanying Unaudited Interim Consolidated Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year.  These financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in the Company’s most recent Form 10-K filed February 23, 2007.

 

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

 

The accounting policies of DENTSPLY International Inc., as applied in the consolidated interim financial statements presented herein, are substantially the same as presented on pages 56 through 63 of the Annual Report on Form 10-K for the fiscal year ended December 31, 2006, except for the following:

 

FIN 48  

 

In June 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48 (“FIN 48”), “Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, Accounting for Income Taxes,” which clarifies the accounting for income taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Interpretation requires that the Company recognize in the financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The provisions of FIN 48 are effective beginning January 1, 2007 with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. As a result of the implementation the Company recognized a $3.8 million increase to reserves for uncertain tax positions.

 

The total amount of gross unrecognized tax benefits, as of the date of adoption, is approximately $48.7 million. Of this total, approximately $37.8 million (net of the federal benefit of state issues) represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date of the Company’s consolidated financial statements. Expiration of statutes of limitation could include unrecognized tax benefits for acquisition and tax restructuring activities of approximately $4.0 million, $2.0 million of which will have no impact upon the effective income tax rate.

 

As a result of the adoption of FIN 48, the Company had a material change to the scheduled contractual cash obligations disclosed in its 2006 Annual Report on Form 10-K filed February 23, 2007. As of June 30, 2007, the Company’s contractual obligation related to the adoption of FIN 48 is $48.7 million.

 

The total amounts of interest and penalties, as of the date of adoption, are $7.8 million and $3.9 million, respectively. The Company has consistently classified interest and penalties recognized in its consolidated financial statements as income taxes based on the accounting policy election of the Company.

 

The Company is subject to United States federal income tax as well as income tax of multiple state and foreign jurisdictions. The significant jurisdictions include the United States, Switzerland and Germany. The Company has substantially concluded all United States federal income tax matters for years through 2003, resulting in the years 2004 through 2006 being subject to future potential tax audit adjustments while years prior to 2004 are settled. The Company is not currently under audit for United States Federal Income Tax purposes. The taxable years that remain open for Switzerland are years 1996 through 2006. For Germany the open years are from 1998 through 2006.

 

 

 


Accounts and Notes Receivable-Trade

 

Accounts and notes receivable-trade are stated net of allowances for doubtful accounts and trade discounts, which were $18.2 million and $16.6 million at June 30, 2007 and December 31, 2006, respectively.

 

Revisions in Classification

 

 

Certain revisions of classification have been made to prior years’ data in order to conform to current year presentation.

 

New Accounting Pronouncements

 

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159 (“SFAS 159”), “The Fair Value Option for Financial Assets and Financial Liabilities.” SFAS 159 permits entities to choose to measure financial instruments and certain other items at fair value that are not currently required to be measured at fair value. This will allow entities the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently. SFAS 159 is effective for financial statements issued for fiscal years ending after November 15, 2007. The Statement should not be applied retrospectively to fiscal years beginning prior to that effective date, except as permitted for early adoption. The Company is currently evaluating the impact of adopting SFAS 159 on the financial statements.

 

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157 (“SFAS 157”), “Fair Value Measurements,” which requires the Company to define fair value, establish a framework for measuring fair value in GAAP, and expand disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company is currently evaluating the impact of adopting SFAS 157 on the financial statements.

 

NOTE 2 – STOCK COMPENSATION  

 

The Company has stock options outstanding under three stock option/equity incentive plans (1993 Plan, 1998 Plan and 2002 Amended and Restated Plan (“the 2002 Plan”)). Further grants can only be made under the 2002 Plan. Under the 1993 and 1998 Plans, a committee appointed by the Board of Directors granted to key employees and directors of the Company, options to purchase shares of common stock at an exercise price determined by the fair market value of the common stock on the date of grant. Stock options generally expire ten years after the date of grant under these plans and grants become exercisable over a period of three years after the date of grant at the rate of one-third per year, except when they become immediately exercisable upon death, disability or qualified retirement.

 

Effective May 15, 2007, the stockholders of the Company approved an amendment to the 2002 Plan. The purpose of the amendment was to eliminate the automatic stock option grants to outside directors and include performance criteria with respect to the grant of performance-based restricted stock and restricted stock units. Under the amended 2002 Plan, no more than 2.0 million shares may be awarded as restricted stock and restricted stock units, and no key employee may be granted in excess of 150,000 shares of common stock in any calendar year.

 

The 2002 Plan authorized grants of 14.0 million shares of common stock, plus any unexercised portion of canceled or terminated stock options granted under the DENTSPLY International Inc. 1993 and 1998 Plans, subject to adjustment as follows: each January, if 7% of the outstanding common shares of the Company exceed 14.0 million, the excess becomes available for grant under the Plan. The 2002 Plan enables the Company to grant "incentive stock options" (“ISOs”) within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, to key employees of the Company, and “non-qualified stock options” (“NSOs”), which do not constitute ISOs to key employees and non-employee directors of the Company. The 2002 Plan also enables the Company to grant stock, which is subject to certain forfeiture risks and restrictions (“Restricted Stock”), stock delivered upon vesting of units (“Restricted Stock Units” or “RSUs”) and stock appreciation rights (“SARs”). ISOs and NSOs are collectively referred to as “options.” Options, Restricted Stock, Restricted Stock Units and SARs are collectively referred to as “awards.” Such awards are granted at exercise prices not less than the fair market value of the common stock on the grant date. The number of shares available for grant under the 2002 Plan as of June 30, 2007 was 6,585,835 shares.

 

Non-Qualified Stock Options

 

The total compensation cost related to non-qualified stock options recognized in the operating results for the three months and six months ended June 30, 2007 was $3.1 million and $6.2 million, respectively. The total compensation cost related to non-qualified stock options recognized in the operating results for the three months and six months ended June 30, 2006 was $4.2 million and $8.5 million, respectively, including the cost for stock-based awards granted prior to January 1, 2006, but not yet vested as of that date. These costs were allocated appropriately to either cost of products sold or selling, general and

 

 

 


administrative expenses. The associated future income tax benefit recognized during the three months and six months ended June 30, 2007 was $0.8 million and $1.6 million, respectively. The associated future income tax benefit recognized during the three months and six months ended June 30, 2006 was $1.3 million and $2.4 million, respectively.

 

There were 3,175,258 non-qualified stock options unvested as of June 30, 2007. The remaining unamortized compensation cost related to non-qualified stock options is $17.6 million, which will be expensed over the weighted average remaining vesting period of the options, or 1.4 years. Cash received from stock option exercises for the three months and six months ended June 30, 2007 was $13.0 million and $26.3 million, respectively. It is the Company’s practice to issue shares from treasury stock when options are exercised. The estimated cash tax benefit to be realized for the options exercised in the three months and six months ended June 30, 2007 was $4.6 million and $7.2 million, respectively. The aggregate intrinsic value of stock options exercised in the three months and six months ended June 30, 2007 was $13.1 million and $21.6 million, respectively. The aggregate intrinsic value of the outstanding stock options as of June 30, 2007 was $148.1 million.

 

Under SFAS 123(R), the Company continues to use the Black-Scholes option-pricing model to estimate the fair value of each option awarded. The following table sets forth the assumptions used to determine compensation cost for our non-qualified stock options issued during the three months and six months ended June 30, 2007:

 

 

 

 

Weighted Average

 

 

 

Weighted Average

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

June 30, 2007

 

 

 

June 30, 2007

Per share fair value

$             8.80

 

 

 

$             8.63

Expected dividend yield

0.44%

 

 

 

0.48%

Risk-free interest rate

4.61%

 

 

 

4.56%

Expected volatility

20%

 

 

 

18%

Expected life (years)

4.43

 

 

 

5.42

 

The following is a summary of the status of the Plans as of June 30, 2007 and changes during the quarter then ended:

 

 

Outstanding

 

Exercisable

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

Weighted

 

 

 

Average

 

 

 

Average

 

 

 

Exercise

 

 

 

Exercise

 

Shares

 

Price

 

Shares

 

Price

 

 

 

 

 

 

 

 

December 31, 2006

11,563,791

 

$            22.97

 

7,912,549

 

$             20.21

Granted

145,600

 

33.68

 

 

 

 

Exercised

(1,400,447)

 

18.79

 

 

 

 

Expired/Canceled

(148,169)

 

28.10

 

 

 

 

 

 

 

 

 

 

 

 

June 30, 2007

10,160,775

 

$            23.63

 

6,985,517

 

$             20.95

 

 

The weighted average remaining contractual term of all outstanding options is 6.4 years and the weighted average remaining contractual term of exercisable options is 5.3 years.

 

Restricted Stock Units

 

During the first quarter of 2007, the Company granted 214,470 RSUs to key employees. The RSUs have a weighted-average fair value per share of $30.76, which was the fair value of the Company’s stock as measured on the date of grant. RSUs vest 100% on the third anniversary of the date of grant and are subject to a service condition, which requires grantees to remain employed by the Company during the three year period following the date of grant. In addition to the service condition, certain key executives may be subject to performance requirements. Under the terms of the RSUs, the three year period is referred to as the restricted period. RSUs and the rights under the award may not be sold, assigned, transferred, donated, pledged or otherwise disposed of during the three year restricted period prior to vesting. Upon the expiration of the applicable restricted period and the satisfaction of all conditions imposed, all restrictions imposed on Restricted Stock Units will lapse, and one share of common stock will be issued as payment for each vested RSU.

 

During the restricted period, the Company will pay cash dividends on the RSUs, in the form of additional RSUs on each date that the Company pays a cash dividend to holders of common stock. The additional RSUs are subject to the same terms and conditions as the original RSUs and vest when the restrictions lapse.

 

 

 


The total compensation cost related to RSUs recognized in the operating results for the three months and six months ended June 30, 2007 was $0.5 million and $0.8 million, respectively. These amounts represent the aggregate fair value of stock units that were expensed during the second quarter and first half of 2007, but not yet vested as of that date. These costs were included in the cost of products sold and selling, general and administrative expenses. The associated future income tax benefit recognized during the three months and six months ended June 30, 2007 was $0.1 million and $0.2 million, respectively. All 214,731 RSUs and RSU dividends remained unvested as of June 30, 2007. The unamortized compensation cost related to RSUs is $5.1 million, which will be expensed over the remaining restricted period of the RSUs, or 2.7 years. The aggregate intrinsic value of the outstanding RSUs as of June 30, 2007 was $8.2 million.

 

NOTE 3 – COMPREHENSIVE INCOME

 

The components of comprehensive income, net of tax, are as follows:

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2007

 

2006

 

2007

 

2006

 

 

(in thousands)

Net income

$          65,433

 

$          59,316

 

$      123,905

 

$    109,320

Other comprehensive income:

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

14,168

 

34,778

 

27,536

 

48,884

 

Unrealized gain on available-for-sale securities

(41)

 

(96)

 

(138)

 

41

 

Amortization of unrecognized losses

 

 

 

 

 

 

 

 

and prior year service cost, net

150

 

-

 

401

 

-

 

Net loss on derivative financial instruments

(163)

 

(30,730)

 

(5,855)

 

(37,633)

Total comprehensive income

$          79,547

 

$          63,268

 

$      145,849

 

$    120,612

 

 

During the quarter ended June 30, 2007, foreign currency translation adjustments included currency translation gains of $10.1 million and gains of $4.1 million on the Company’s loans designated as hedges of net investments. During the quarter ended June 30, 2006, foreign currency translation adjustments included currency translation gains of $42.6 million and partially offset by losses of $7.9 million on the Company’s loans designated as hedges of net investments. During the six months ended June 30, 2007, foreign currency translation adjustments included currency translation gains of $24.7 million and gains of $2.8 million on the Company’s loans designated as hedges of net investments. During the six months ended June 30, 2006, foreign currency translation adjustments included currency translation gains of $60.7 million offset by losses of $11.8 million on the Company’s loans designated as hedges of net investments. As a result of the Company’s adoption of Statement of Financial Accounting Standards No. 158 (“SFAS 158”) on January 1, 2007, the Company recognized $0.4 million of the unrecognized losses and prior service cost, net in comprehensive income. The $0.4 million was derived using the average exchange rate for the current period, which may differ from the exchange rate used to record the unrecognized losses and prior service cost, net.

 

The balances included in accumulated other comprehensive income in the consolidated balance sheets are as follows:

 

 

 

June 30,

 

December 31,

 

 

2007

 

2006

 

 

(in thousands)

Foreign currency translation adjustments

$        162,877

 

$         135,341

Net loss on derivative financial instruments

(38,420)

 

(32,565)

Unrealized gain on available-for-sale securities

195

 

333

Unrecognized losses and prior service cost, net

(22,794)

 

(23,195)

 

 

$        101,858

 

$          79,914

 

 

The cumulative foreign currency translation adjustments included translation gains of $241.7 million and $216.9 million as of June 30, 2007 and December 31, 2006, respectively, offset by losses of $78.8 million and $81.6 million, respectively, on loans designated as hedges of net investments.

 

 

 

 


NOTE 4 - EARNINGS PER COMMON SHARE

 

The dilutive effect of outstanding options and restricted stock is reflected in diluted earnings per share by application of the treasury stock method, which in the current period includes consideration of stock-based compensation required by SFAS No. 123(R). The following table sets forth the computation of basic and diluted earnings per common share:

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands, except per share amounts)

Basic Earnings Per Common Share Computation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

$      65,433

 

$      59,316

 

$    123,905

 

$    109,320

 

 

 

 

 

 

 

 

Common shares outstanding

152,000

 

156,814

 

152,016

 

157,402

 

 

 

 

 

 

 

 

Earnings per common share - basic

$            0.43

 

$          0.38

 

$           0.82

 

$           0.69

 

 

 

 

 

 

 

 

Diluted Earnings Per Common Share Computation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

$      65,433

 

$      59,316

 

$    123,905

 

$    109,320

 

 

 

 

 

 

 

 

Common shares outstanding

152,000

 

156,814

 

152,016

 

157,402

Incremental shares from assumed exercise

 

 

 

 

 

 

 

of dilutive options

2,873

 

3,020

 

2,707

 

3,044

Total shares

154,873

 

159,834

 

154,723

 

160,446

 

 

 

 

 

 

 

 

Earnings per common share - diluted

$            0.42

 

$          0.37

 

$           0.80

 

$           0.68

 

 

There were no options to purchase shares of common stock outstanding during the quarters ended June 30, 2007 and 2006 that had an anti-dilutive effect on the computation of diluted earnings per share.

 

NOTE 5 - BUSINESS ACQUISITIONS

 

During the second quarter of 2007, the Company acquired three businesses for a total cost of approximately $19.0 million, net of cash acquired. The following list provides information about the acquired companies:

 

 

NEKS Technologies, Inc. is a dental equipment manufacturer in Canada, which develops and commercializes proprietary, non-invasive, handheld dental instruments for early diagnosis of pathologies;

 

 

TMV Medica is a sales and marketing organization for implant products in Spain; and

 

 

Sportswire is a manufacturer of endodontic materials based in Oklahoma.

 

The NEKS Technologies, Inc. purchase agreement also provides for an additional payment to be made based upon the operating performance of the business through 2010. The results of operations for the three businesses have been included in the accompanying financial statements since the effective date of the respective transaction.

 

The purchase prices have been allocated on the basis of preliminary estimates of the fair values of assets acquired and liabilities assumed. As a result of the 2007 acquisitions, the Company has recorded a total of $16.7 million in goodwill related to the unallocated portions of the respective purchase prices.

 

Several of the Company’s 2005 acquisitions included provisions for possible additional payments based on the performance of the individual businesses post closing (generally for two to three years). During the first half of 2007, the Company paid $7.2 million in additional purchase price under these agreements.

 

 

 


NOTE 6 - SEGMENT INFORMATION

 

The Company follows Statement of Financial Accounting Standards No. 131 ("SFAS 131"), “Disclosures about Segments of an Enterprise and Related Information.” SFAS 131 establishes standards for disclosing information about reportable segments in financial statements. The Company has numerous operating businesses covering a wide range of products and geographic regions, primarily serving the professional dental market. Professional dental products represented approximately 97% of sales for the periods ended June 30, 2007 and 2006.

 

The operating businesses are combined into operating groups which have overlapping product offerings, geographical presence, customer bases, distribution channels, and regulatory oversight. These operating groups are considered the Company’s reportable segments under SFAS 131 as the Company’s chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company’s operations. The accounting policies of the groups are consistent with those described in the most recently filed 10-K Consolidated Financial Statements in the summary of significant accounting policies. The Company measures segment income for reporting purposes as net operating profit before restructuring, interest and taxes.

 

In January 2007, the Company reorganized its operating group structure expanding into four operating groups from the three groups under the prior management structure. The segment information below reflects this revised structure and the services provided with each segment for all periods shown.

 

United States, Germany, and Certain Other European Regions Consumable Businesses

 

This business group includes responsibility for the design, manufacturing, sales, and distribution for certain small equipment and chairside consumable products in the United States, Germany, and certain other European regions.

 

France, United Kingdom, Italy, CIS, Middle East, Africa, Pacific Rim Businesses

 

This business group includes responsibility for the sales and distribution for chairside consumable products and certain small equipment, certain laboratory products, and certain Endodontic products in France, United Kingdom, Italy, the Commonwealth of Independent States (“CIS”), Middle East, Africa, Asia, Japan, and Australia, as well as the sale and distribution of implant products and bone substitute/grafting materials in Italy, Asia and Australia. This business group also includes the manufacturing and sale of Orthodontic products, the manufacturing of certain laboratory products in Japan, and the manufacturing of certain laboratory and certain Endodontic products in Asia.

 

Canada/Latin America/Endodontics/Orthodontics

 

This business group includes responsibility for the design, manufacture, and/or sales and distribution of chairside consumable and laboratory products in Brazil. It also has responsibility for the sales and distribution of most Company dental products sold in Latin America and Canada. This business group also includes the responsibility for the design and manufacturing for Endodontic products in the United States, Switzerland and Germany and is responsible for sales and distribution of certain Company Endodontic products in the United States, Canada, Switzerland, Benelux, Scandinavia, and Eastern Europe, and certain Endodontic products in Germany. This business group is also responsible for the world-wide sales and distribution, excluding Japan, as well as some manufacturing of the Company’s Orthodontic products. This business group is also responsible for sales and distribution in the United States for implant and bone substitute/grafting materials and the distribution of implants in Brazil.

 

Global Dental Laboratory Business/Implants/Non-Dental

 

This business group includes the responsibility for the design, manufacture, world-wide sales and distribution for laboratory products, excluding certain laboratory products mentioned earlier, and the design, manufacture, and/or sales and distribution of the Company’s dental implant products and bone substitute/grafting materials, excluding sales and distribution of implants and bone substitute/grafting materials in the United States, Italy, Australia and Brazil. This business group is also responsible for the Company’s non-dental business.

 

Significant interdependencies exist among the Company’s operations in certain geographic areas. Inter-group sales are at prices intended to provide a reasonable profit to the manufacturing unit after recovery of all manufacturing costs and to provide a reasonable profit for purchasing locations after coverage of marketing and general and administrative costs.

 

 

 


Generally, the Company evaluates performance of the operating groups based on the groups’ operating income and net third party sales excluding precious metal content. The following tables set forth information about the Company’s operating groups for the three months and six months ended June 30, 2007 and 2006:

 

Third Party Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands)

 

 

 

 

 

 

 

 

U.S., Germany, and Certain Other European

 

 

 

 

 

 

Regions Consumable Businesses

$   106,221

 

$  106,725

 

$  206,634

 

$ 198,149

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

98,005

 

85,750

 

184,710

 

160,289

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

Orthodontics

149,374

 

135,376

 

284,453

 

260,979

Global Dental Laboratory Business/

 

 

 

 

 

 

 

Implants/Non-Dental

154,703

 

145,782

 

306,743

 

286,038

All Other (a)

(941)

 

(1,189)

 

(2,314)

 

(2,015)

Total

$   507,362

 

$  472,444

 

$  980,226

 

$ 903,440

 

 

 

Third Party Net Sales, excluding precious metal content

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands)

 

 

 

 

 

 

 

 

U.S., Germany, and Certain Other European

 

 

 

 

 

 

Regions Consumable Businesses

$   106,221

 

$  106,726

 

$  206,634

 

$       198,150

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

92,029

 

80,413

 

172,063

 

149,356

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

Orthodontics

148,496

 

134,474

 

282,479

 

259,306

Global Dental Laboratory Business/

 

 

 

 

 

 

 

Implants/Non-Dental

116,303

 

103,100

 

226,512

 

202,142

All Other (a)

(941)

 

(1,189)

 

(2,314)

 

(2,015)

Total excluding Precious Metal Content

462,108

 

423,524

 

885,374

 

806,939

Precious Metal Content

45,254

 

48,920

 

94,852

 

96,501

Total including Precious Metal Content

$   507,362

 

$  472,444

 

$  980,226

 

$       903,440

 

 

(a) Includes: amounts recorded at Corporate headquarters.

 

 

 


 

Intersegment Net Sales

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands)

 

 

 

 

 

 

 

 

U.S., Germany, and Certain Other European

 

 

 

 

 

 

Regions Consumable Businesses

$         35,480

 

$            37,541

 

$         72,368

 

$         69,463

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

4,053

 

2,424

 

6,374

 

4,749

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

Orthodontics

23,293

 

19,603

 

44,819

 

36,706

Global Dental Laboratory Business/

 

 

 

 

 

 

 

Implants/Non-Dental

22,976

 

17,914

 

48,368

 

34,553

All Other (a)

36,279

 

33,722

 

72,201

 

63,745

Eliminations

(122,081)

 

(111,204)

 

(244,130)

 

(209,216)

Total

$ -

 

$ -

 

$ -

 

$ -

 

 

 

Segment Operating Income

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2007

 

2006

 

2007

 

2006

 

(in thousands)

 

 

 

 

 

 

 

 

U.S., Germany, and Certain Other European

 

 

 

 

 

 

Regions Consumable Businesses

$            37,869

 

$        40,902

 

$        71,802

 

$       71,071

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

4,141

 

2,001

 

4,718

 

720

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

Orthodontics

45,088

 

45,036

 

87,555

 

88,766

Global Dental Laboratory Business/

 

 

 

 

 

 

 

Implants/Non-Dental

28,893

 

23,895

 

57,527

 

47,752

All Other (b)

(19,291)

 

(22,606)

 

(42,701)

 

(44,376)

Segment Operating Income

96,700

 

89,228

 

178,901

 

163,933

 

 

 

 

 

 

 

 

Reconciling Items:

 

 

 

 

 

 

 

Restructuring and other costs

(3,207)

 

(2,636)

 

(4,197)

 

(7,333)

Interest Expense

(5,209)

 

(8,765)

 

(9,665)

 

(16,145)

Interest Income

6,995

 

9,204

 

13,496

 

17,271

Other income (expense), net

347

 

(965)

 

557

 

(451)

Income before income taxes

$            95,626

 

$        86,066

 

$      179,092

 

$     157,275

 

 

(a) Includes: the results of one distribution warehouse not managed by named segments and Corporate.

 

(b) Includes: the results of one distribution warehouse not managed by named segments, Corporate and inter-segment eliminations.

 

 

 


 

Assets

 

 

 

 

June 30,

 

December 31,

 

2007

 

2006

 

(in thousands)

 

 

 

 

U.S., Germany, and Certain Other European

 

 

Regions Consumable Businesses

$              282,347

 

$             273,233

France, U.K., Italy, CIS, Middle East,

 

 

 

Africa, Pacific Rim Businesses

287,070

 

271,999

Canada/Latin America/Endodontics/

 

 

 

Orthodontics

738,630

 

705,321

Global Dental Laboratory Business/

 

 

 

Implants/Non-Dental

720,140

 

682,879

All Other (a)

360,383

 

247,918

Total

$          2,388,570

 

$          2,181,350

 

 

(a) Includes: assets of one distribution warehouse not managed by named segments, Corporate and inter-segment eliminations.

 

NOTE 7 - INVENTORIES

 

Inventories are stated at the lower of cost or market. At June 30, 2007 and December 31, 2006, the cost of $10.8 million, or 4.3%, and $11.2 million, or 4.8%, respectively, of inventories was determined by the last-in, first-out (“LIFO”) method. The cost of other inventories was determined by the first-in, first-out (“FIFO”) or average cost methods. The Company establishes reserves for inventory estimated to be obsolete or unmarketable equal to the difference between the cost of inventory and estimated market value based upon assumptions about future demand and market conditions. The inventory valuation reserves were $28.0 million and $26.3 million as of June 30, 2007 and December 31, 2006, respectively.

 

If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at June 30, 2007 and December 31, 2006 by $3.6 million and $3.3 million, respectively.

 

Inventories, net of inventory valuation reserves, consist of the following:

 

 

 

June 30,

 

December 31,

 

 

2007

 

2006

 

 

(in thousands)

 

 

 

 

 

Finished goods

 

$           157,433

 

$           143,167

Work-in-process

 

47,167

 

43,855

Raw materials and supplies

45,264

 

45,419

 

 

$           249,864

 

$           232,441

 

 

 

 

 


NOTE 8 - BENEFIT PLANS

 

The Company adopted SFAS 158 for the year ended December 31, 2006 using the prospective method as required by the statement. The Company has early adopted the provision of SFAS 158 that requires the alignment of the measurement date and the year-end balance sheet date for the 2007 fiscal year. The net of tax adjustment to retained earnings was $0.4 million.

 

The following sets forth the components of net periodic benefit cost of the Company’s benefit plans and for the Company’s other postretirement employee benefit plans for the three and six months ended June 30, 2007 and June 30, 2006, respectively:

 

 

 

 

 

 

 

Other Postretirement

 

 

Pension Benefits

 

Benefits

 

 

Three Months Ended

 

Three Months Ended

 

 

June 30,

 

June 30,

 

 

2007

 

2006

 

2007

 

2006

 

 

(in thousands)

Service cost

 

$     1,635

 

$     1,644

 

$           16

 

$        23

Interest cost

 

1,650

 

1,499

 

130

 

196

Expected return on plan assets

 

(895)

 

(955)

 

-

 

-

Amortization of transition obligation

54

 

53

 

-

 

-

Amortization of prior service cost

24

 

28

 

(96)

 

(199)

Amortization of net loss

 

314

 

267

 

31

 

80

 

 

 

 

 

 

 

 

 

Net periodic benefit cost

 

$     2,782

 

$     2,536

 

$           81

 

$      100

 

 

 

 

 

 

 

 

 

Other Postretirement

 

 

Pension Benefits

 

Benefits

 

 

Six Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

 

 

2007

 

2006

 

2007

 

2006

 

 

(in thousands)

Service cost

 

$      3,314

 

$     3,226

 

$          32

 

$        46

Interest cost

 

3,431

 

2,942

 

261

 

392

Expected return on plan assets

 

(2,000)

 

(1,864)

 

-

 

-

Amortization of transition obligation

107

 

103

 

-

 

-

Amortization of prior service cost

61

 

57

 

(193)

 

(397)

Amortization of net loss

 

598

 

514

 

62

 

159

 

 

 

 

 

 

 

 

 

Net periodic benefit cost

 

$      5,511

 

$     4,978

 

$        162

 

$     200

 

 

The following sets forth the information related to the funding of the Company’s benefit plans for 2007:

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Pension

 

Postretirement

 

 

 

 

 

 

Benefits

 

Benefits

 

 

 

 

 

 

(in thousands)

Actual, June 30, 2007

 

 

 

 

 

$       3,605

 

$                 1,143

Projected for the remainder of the year

 

 

 

 

2,887

 

1,150

Total for year

 

 

 

 

 

$       6,492

 

$                 2,293

 

 

 

 


NOTE 9 - RESTRUCTURING AND OTHER COSTS (INCOME), NET

 

Restructuring Costs

 

2007 Plans

 

During 2007, the Company initiated several restructuring plans primarily related to the closure and consolidation of certain production and selling facilities in South America in order to better leverage the Company’s resources by reducing costs and obtaining operational efficiencies. During the six months ended June 30, 2007, the Company recorded charges of $0.7 million for severance and other restructuring costs. The major components of these charges and the remaining outstanding balances at June 30, 2007 are as follows:

 

 

 

 

Amounts

 

Balance

 

2007

 

Applied

 

June 30,

 

Provisions

 

2007

 

2007

 

(in thousands)

Severance

$             247

 

$             -

 

$         247

Other restructuring costs

428

 

(96)

 

332

 

$             675

 

$         (96)

 

$         579

 

 

2006 Plans

 

During 2006, the Company initiated several restructuring plans primarily related to the closure and consolidation of certain production and selling facilities in the United States and Europe in order to better leverage the Company’s resources by reducing costs and obtaining operational efficiencies. During the six months ended June 30, 2007, the Company recorded charges of $1.2 million for additional severance and other restructuring costs. The plans include the elimination of approximately 90 positions, with 42 of these positions having been eliminated as of June 30, 2007. These plans are expected to be substantially completed by the end of 2007. The major components of these charges and the remaining outstanding balances at June 30, 2007 are as follows:

 

 

 

 

Amounts

 

 

 

Amounts

 

Balance

 

2006

 

Applied

 

2007

 

Applied

 

June 30,

 

Provisions

 

2006

 

Provisions

 

2007

 

2007

 

(in thousands)

Severance

$          2,205

 

$ -

 

$             339

 

$       (836)

 

$           1,708

Lease/Contract terminations

-

 

-

 

33

 

(33)

 

-

Other restructuring costs

73

 

-

 

851

 

(523)

 

401

 

$          2,278

 

$ -

 

$          1,223

 

$    (1,392)

 

$           2,109

 

 

2005 Plans

 

During 2005, the Company initiated several restructuring plans primarily related to the shutdown of the pharmaceutical manufacturing facility outside of Chicago. In addition, these costs related to the consolidation of certain United States production facilities in order to better leverage the Company’s resources. The primary objective of these initiatives is to reduce costs and obtain operational efficiencies. As of June 30, 2007, the shutdown of the pharmaceutical manufacturing facility has been completed. During the six months ended June 30, 2007, the Company recorded charges of $0.2 million primarily for additional severance costs and other restructuring costs. The plans include the elimination of approximately 155 administrative and manufacturing positions, all within the United States, with 146 of these positions having been eliminated as of June 30, 2007. The Company does not expect any significant future expenses related to these plans. The major components of these charges and the remaining outstanding balances at June 30, 2007 are as follows:

 

 

 

 

 

 

Amounts

 

Change in

 

 

 

Amounts

 

Change in

 

Balance

 

2005

 

2006

 

Applied

 

Estimate

 

2007

 

Applied

 

Estimate

 

June 30,

 

Provisions

 

Provisions

 

2006

 

2006

 

Provisions

 

2007

 

2007

 

2007

 

(in thousands)

 

 

 

Severance

$          2,400

 

$          3,570

 

$     (4,420)

 

$        (523)

 

$             235

 

$        (731)

 

$          (12)

 

$         519

Lease/contract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

terminations

-

 

184

 

(184)

 

-

 

-

 

-

 

-

 

-

Other restructuring

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

costs

-

 

5,882

 

(5,882)

 

-

 

-

 

-

 

-

 

-

 

$          2,400

 

$          9,636

 

$   (10,486)

 

$        (523)

 

$             235

 

$        (731)

 

$          (12)

 

$         519

 

 

 

 


2004 Plans

 

During 2004, the Company initiated several restructuring plans primarily related to the creation of a European Shared Services Center in Yverdon, Switzerland, which resulted in the identification of redundant personnel in the Company’s European accounting functions. In addition, these costs related to the consolidation of certain sales/customer service and distribution facilities in Europe and Japan. The primary objective of these restructuring initiatives is to improve operational efficiencies and to reduce costs within the related businesses. The plans include the elimination of approximately 105 administrative and manufacturing positions primarily in Germany. Certain of these positions are being replaced at the European Shared Services Center and therefore the net reduction in positions is expected to be approximately 55. As of June 30, 2007, 42 of these positions have been eliminated. These plans are expected to be fully completed in early 2008. The major components of these charges and the remaining outstanding balances at June 30, 2007 are as follows:

 

 

 

 

 

Amounts

 

 

 

Change in

 

Amounts

 

Balance

 

 

 

 

 

 

2004

 

Applied

 

2005

 

Estimate

 

Applied

 

Year Ended

 

 

 

 

 

 

Provisions

 

2004

 

Provisions

 

2005

 

2005

 

2005

 

 

 

 

 

 

(in thousands)

 

 

 

Severance

$           4,877

 

$          (583)

 

$            322

 

$     (1,168)

 

$       (1,740)

 

$       1,708

 

 

 

 

Lease/contract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

terminations

881

 

-

 

190

 

-

 

(435)

 

636

 

 

 

 

 

 

$           5,758

 

$          (583)

 

$            512

 

$     (1,168)

 

$       (2,175)

 

$       2,344

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance

 

 

 

Amounts

 

Change in

 

 

 

Amounts

 

Change in

 

Balance

 

 

Year Ended

 

2006

 

Applied

 

Estimate

 

2007

 

Applied

 

Estimate

 

June 30,

 

 

2005

 

Provisions

 

2006

 

2006

 

Provisions

 

2007

 

2007

 

2007

 

 

(in thousands)

Severance

$           1,708

 

$            118

 

$          (632)

 

$        (275)

 

$             40

 

$        (181)

 

$         (33)

 

$         745

Lease/contract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

terminations

636

 

-

 

(204)

 

-

 

-

 

(56)

 

-

 

376

 

 

$           2,344

 

$            118

 

$          (836)

 

$        (275)

 

$             40

 

$        (237)

 

$         (33)

 

$      1,121

 

Other Costs

 

During the quarter ended June 30, 2007, the Company paid a total of $2.1 million related to several legal settlements.

 

NOTE 10 – FINANCIAL INSTRUMENTS AND DERIVATIVES

 

The Company uses interest rate swaps, cross currency interest rate swaps, commodity swaps, forward exchange contracts, and foreign currency denominated debt held at the parent company level to manage risks generally associated with foreign exchange rates, interest rates and commodity price fluctuations. For a more detailed discussion of the Company’s derivative instruments, refer to the Company’s 2006 Annual Report on Form 10-K.

 

Cash Flow Hedges

 

The Company uses interest rate swaps to convert a portion of its variable rate debt to fixed rate debt. The Company selectively enters into commodity swaps to effectively fix certain variable raw material costs. The Company enters into forward exchange contracts to hedge the foreign currency exposure of its anticipated purchases of certain inventory from Japan. In addition, forward exchange contracts are used by certain of the Company’s subsidiaries to hedge intercompany inventory purchases, which are denominated in non-local currencies.

 

Amounts recorded in accumulated other comprehensive income (loss) related to cash flow hedging instruments follow:

 

 

 

 

 

 

Three Months Ended  

 

Six Months Ended

 

 

 

 

 

June 30,

 

June 30,

Net of Tax

 

 

 

 

2007

 

2006

 

2007

 

2006

 

 

 

 

 

 

 

(in thousands)

 

 

Beginning balance

 

 

 

$     (2,757)

 

$     (3,405)

 

$     (3,003)

 

$     (5,856)

 

 

 

 

 

 

 

 

 

 

 

 

Changes in fair value of derivatives 

831

 

388

 

578

 

2,345

Reclassifications to earnings from equity 

249

 

414

 

748

 

908

Total activity

 

 

 

 

1,080

 

802

 

1,326

 

3,253

 

 

 

 

 

 

 

 

 

 

 

 

Ending balance 

 

 

$     (1,677)

 

$    (2,603)

 

$     (1,677)

 

$     (2,603)

 

As of June 30, 2007, $2.0 million of deferred net losses on derivative instruments in accumulated other comprehensive income are expected to be reclassified to current earnings during the next twelve months.

 

 

 


Hedges of Net Investments in Foreign Operations

 

The Company has numerous investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. Currently, the Company uses non-derivative financial instruments, including foreign currency denominated debt held at the parent company level and derivative financial instruments to hedge some of this exposure. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the non-derivative and derivative financial instruments designated as hedges of net investments.

 

Amounts recorded in accumulated other comprehensive income (loss) related to hedges of net investments in foreign operations follow:

 

 

 

 

 

 

Three Months Ended  

 

Six Months Ended

 

 

 

 

 

June 30,

 

June 30,

Net of Tax 

 

 

2007

 

2006

 

2007

 

2006

 

 

 

 

 

 

 

(in thousands)

 

 

Beginning balance

 

 

 

$ 113,678

 

$   81,321

 

$ 106,248

 

$   76,570

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

10,033

 

42,647

 

24,781

 

60,725

Changes in fair value of:

 

 

 

 

 

 

 

 

 

foreign currency debt

 

 

4,135

 

(7,869)

 

2,755

 

(11,841)

derivative hedge instruments 

(1,243)

 

(31,532)

 

(7,181)

 

(40,887)

Total activity

 

 

 

12,925

 

3,246

 

20,355

 

7,997

 

 

 

 

 

 

 

 

 

 

 

 

Ending balance

 

 

 

$ 126,603

 

$   84,567

 

$ 126,603

 

$   84,567

 

Other

 

The aggregate net fair value of the Company’s derivative instruments at June 30, 2007 and December 31, 2006 was negative $62.7 million and negative $53.4 million, respectively.

 

NOTE 11 - COMMITMENTS AND CONTINGENCIES

 

On January 5, 1999, the Department of Justice filed a Complaint against the Company in the United States District Court in Wilmington, Delaware alleging that the Company’s tooth distribution practices violated the antitrust laws and seeking an order for the Company to discontinue its practices. This case has been concluded and the District Court, upon the direction of the Court of Appeals, issued an injunction preventing DENTSPLY from taking action to restrict its tooth dealers from adding new competitive teeth lines. This decision relates only to the distribution of artificial teeth in the United States and, notwithstanding the outcome of this case, the Company is confident that it can continue to develop this business.

 

Subsequent to the filing of the Department of Justice Complaint in 1999, several private party class actions were filed based on allegations similar to those in the Department of Justice case, on behalf of dental laboratories, and denture patients in seventeen states who purchased Trubyte teeth or products containing Trubyte teeth. These cases were transferred to the United States District Court in Wilmington, Delaware. The private party suits seek damages in an unspecified amount. The Court has granted the Company’s Motion on the lack of standing of the laboratory and patient class actions to pursue damage claims. The Plaintiffs in the laboratory case appealed this decision to the Third Circuit and the Court largely upheld the decision of the District Court in dismissing the Plaintiffs’ damages claims against DENTSPLY, with the exception of allowing the Plaintiffs to pursue a damage claim based on a theory of resale price maintenance between the Company and its tooth dealers. The Plaintiffs’ petition to the United States Supreme Court asking it to review this decision of the Third Circuit was denied. The Plaintiffs in the laboratory case filed an amended complaint asserting that DENTSPLY and its tooth dealers, and the dealers among themselves, engaged in a conspiracy to violate the antitrust laws. Dentsply and the dealers have filed Motions to dismiss plaintiffs’ claims, except for the resale price maintenance claims. Additionally, manufacturers of two competitive tooth lines have filed and are pursuing separate actions seeking damages alleged to have been incurred as a result of the Company’s tooth distribution practice found to be a violation of the antitrust law.

 

 

 


On March 27, 2002, a Complaint was filed in Alameda County, California (which was transferred to Los Angeles County) by Bruce Glover, DDS alleging, inter alia, breach of express and implied warranties, fraud, unfair trade practices and negligent misrepresentation in the Company’s manufacture and sale of Advance® cement. The Judge entered an Order granting class certification, as an opt-in class. In general, the Class is defined as California dentists who purchased and used Advance® cement and were required, because of failures of the cement, to repair or reperform dental procedures for which they were not paid. The Notice of the class action was sent on February 23, 2005 to the approximately 29,000 dentists licensed to practice in California during the relevant period and a total of 166 dentists opted into the class action. The plaintiffs appealed the decision of the Trial Court certifying the class as an opt-in and the Appeals Court held that the case should be converted to an opt-out class. The parties have entered a settlement agreement, which was approved by the Court at a fairness hearing on June 15, 2007. The settlement establishes a procedure by which dentists, who believe they were required to perform dental work because of a problem caused by Advance cement, can submit claims for review and reimbursement of unpaid fees. The Advance® cement product was sold from 1994 through 2000 and total sales in the United States during that period were approximately $5.2 million. The Company’s primary level insurance carrier has confirmed coverage for claims in this matter up to one million dollars, their asserted policy limits. Litigation is pending with the Company’s excess insurance carrier regarding the level and coverage of their insurance for this case.

 

On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a class action suit in San Francisco County, California alleging that the Company misrepresented that its Cavitron® ultrasonic scalers are suitable for use in oral surgical procedures. The Complaint seeks a recall of the product and refund of its purchase price to dentists who have purchased it for use in oral surgery. The Court certified the case as a class action in June 2006 with respect to the breach of warranty and unfair business practices claims. The class is defined as California dental professionals who purchased and used one or more Cavitron ultrasonic scalers for the performance of oral surgical procedures. The Company filed a motion for decertification of the class and this motion was granted. Plaintiffs have appealed the decertification of the class to the California Court of Appeals.

 

On December 12, 2006, a Complaint was filed by Carole Hildebrand, DDS and Robert Jaffin, DDS in the Eastern District of PA. The case was filed by the same law firm that filed the Weinstat case in California. The Complaint seeks a refund of the purchase price paid for Cavitron scalers and asserts putative class action claims on behalf of dentists located in New Jersey and Pennsylvania based on assertions that the Cavitron was sold in breach of contract and warranty arising from misrepresentations about the potential uses of the product because it cannot deliver potable or sterile water.

 

NOTE 12 - FINANCING ARRANGEMENTS

 

During the first quarter of 2007, the Company entered into a purchase agreement with a group of initial purchasers, providing for the issuance by the Company of $150.0 million aggregate principal amount of floating rate Senior Notes due 2010 through a private placement. The net proceeds from the offering after deducting placement fees and expenses of the offering were $149.5 million. The obligations of the Company and the initial purchasers are subject to the terms and conditions of the Note Purchase Agreement.

 

NOTE 13 – SUBSEQUENT EVENT

 

On June 14, 2007, the Company entered into a purchase agreement to acquire the assets of Sultan Healthcare, Inc. Sultan Healthcare, Inc., based in New Jersey, is a well-known United States dental consumable manufacturer recognized primarily for infection control products, dental materials and preventive products. The Company purchased Sultan Healthcare, Inc. primarily to expand its product offerings by entering important new categories such as infection control products. It is expected that this acquisition will add approximately $45 to $50 million on an annualized basis to DENTSPLY’s sales. The transaction closed on July 17, 2007.

 

 

 


DENTSPLY International Inc.

 

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, DENTSPLY International Inc. (“the Company”) provided the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by the Company are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate” or words of similar import.

Investors are cautioned that forward-looking statements involve risks and uncertainties, which may materially affect the Company’s business and prospects, and should be read in conjunction with the risk factors and uncertainties discussed within Item 1A, Part I of the Company’s most recent Annual Report on Form 10-K as filed on February 23, 2007. Investors are further cautioned that the risk factors in Item 1A, Part I of Company’s most recent Annual Report on Form 10-K may not be exhaustive and that many of these factors are beyond the Company’s ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. The Company undertakes no duty and has no obligation to update forward-looking statements.

 

OVERVIEW

 

Dentsply International Inc. is the world’s largest manufacturer of professional dental products. The Company is headquartered in the United States, and operates in more than 120 other countries, principally through its foreign subsidiaries. The Company also has strategically located distribution centers to enable it to better serve its customers and increase its operating efficiency. While the United States and Europe are the Company’s largest markets, the Company serves all of the major professional dental markets worldwide.

The principal benchmarks used by the Company in evaluating its business are: (1) internal growth in the United States, Europe and all other regions; (2) operating margins of each reportable segment, (3) the development, introduction and contribution of innovative new products; (4) growth through acquisition; and (5) continued focus on controlling costs and enhancing efficiency. The Company defines "internal growth" as the increase in net sales from period to period, excluding precious metal content, the impact of changes in currency exchange rates, and the net sales, for a period of twelve months following the transaction date, of businesses that have been acquired or divested.

Management believes that an average overall internal growth rate of 4-6% is a long-term sustainable rate for the Company. This annualized growth rate expectation typically includes approximately 1-2% of price increases. The Company typically implements most of its price changes in the beginning of the fourth quarter of the year. These price changes, other marketing and promotional programs offered to customers from time to time in the ordinary course of business, the management of inventory levels by distributors and the implementation of strategic initiatives, may impact sales levels in a given period.

During the six months ended June 30, 2007, the Company’s overall internal growth was approximately 6.3% compared to 4.3% for the full year 2006. Internal growth rates in the United States and Europe, the largest dental markets in the world, were 4.2% and 8.3%, respectively during the first six months of 2007 compared to 1.2% and 7.4%, respectively for the full year 2006. The internal growth rate in all other regions during the six months ended June 30, 2007 was 7.2%, compared to 5.6% for the full year 2006.

 

Product innovation is a key component of the Company’s overall growth strategy. Through the first half of 2007, the Company continued to introduce multiple new products or significant product enhancements. New advances in technology are anticipated to have a significant influence on future products in dentistry. As a result, the Company has pursued several research and development initiatives to support this technological development, including partnerships and collaborations with various research institutions and dental schools. In addition, the Company licenses and purchases technologies developed by other third parties. Although the Company believes these activities will lead to new innovative dental products, they involve new technologies and there can be no assurance that commercialized products will be developed.

 

 

 


Although the professional dental market in which the Company operates has experienced consolidation, it is still a fragmented industry. The Company continues to focus on opportunities to expand the Company’s product offerings through acquisitions and investments in companies. Management believes that there will continue to be adequate opportunities to participate as a consolidator or investor in the industry for the foreseeable future. As further discussed in Note 5 and Note 13 to the Unaudited Interim Consolidated Condensed Financial Statements, the Company has purchased several businesses during 2007.

The Company also remains focused on reducing costs and achieving operational efficiencies. Management expects to continue to consolidate operations or functions to reduce costs while improving service levels. In addition, the Company remains focused on enhancing efficiency through expanded use of technology, process improvement initiatives and new marketing strategies. The Company believes that the benefits from these opportunities will improve the cost structure and offset areas of rising costs such as energy, benefits, regulatory oversight and compliance and financial reporting.

In 2006, the Company entered into a new U.S.-based Strategic Partnership Program, designed to significantly improve its ability to collaborate with and provide value to its key distributor partners. This program encompasses all of the Company’s divisions selling through United States dental distributors and has resulted in a consolidated network of United States distributors, which represented over 90% of the Company’s distributor-based business in the United States.

 

RESULTS OF OPERATIONS, QUARTER ENDED JUNE 30, 2007 COMPARED TO QUARTER ENDED JUNE 30, 2006

 

Net Sales

 

The discussion below summarizes the Company’s sales growth, excluding precious metals, from internal growth and net acquisition growth and highlights the impact of foreign currency translation. The recent acquisitions did not have a significant impact on sales growth during the first half of 2007. These disclosures of net sales growth provide the reader with sales results on a comparable basis between periods.

 

Management believes that the presentation of net sales excluding precious metal content provides useful information to investors because a significant portion of DENTSPLY’s net sales is comprised of sales of precious metals generated through sales of the Company’s precious metal alloy products, which are used by third parties to construct crown and bridge solutions. Due to the fluctuations of precious metal prices and because the precious metal content of the Company’s sales is largely a pass-through to customers and has minimal effect on earnings, DENTSPLY reports sales both with and without precious metal content to show the Company’s performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal alloy sale prices are typically adjusted when the prices of underlying precious metals change.

 

As the presentation of net sales excluding precious metal content could be considered a measure not calculated in accordance with generally accepted accounting principles (a non-GAAP measure), the Company provides the following reconciliation of net sales to net sales excluding precious metal content. The Company’s definitions and calculations of net sales excluding precious metal content and other operating measures derived using net sales excluding precious metal content may not necessarily be the same as those used by other companies.

 

 

 

Three Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(in millions)

 

 

Net sales

 

$          507.4

 

$          472.4

 

$            35.0

 

7.4%

Precious metal content of sales

 

(45.3)

 

(48.9)

 

3.6

 

-7.4%

Net sales excluding precious metal content

$          462.1

 

$          423.5

 

$            38.6

 

9.1%

 

 

The net sales growth of 9.1%, excluding precious metal content, was comprised of 6.3% of internal growth and 2.8% of foreign currency translation. The 6.3% internal growth was comprised of 3.8% in the United States, 8.2% in Europe and 8.2% for all other regions combined.

 

 

 


Internal Sales Growth

 

 

 

Three Months Ended

 

 

June 30,

 

 

2007

 

2006

United States

 

3.8%

 

6.1%

Europe

 

8.2%

 

5.0%

Other regions

 

8.2%

 

3.5%

 

 

United States

 

The internal sales growth of 3.8%, excluding precious metal content, in the United States was primarily a result of improvement in growth rates for our laboratory products, continued growth in the Implants and Orthodontics categories and modest growth in the dental consumable category.

 

Europe

 

In Europe, the internal sales growth of 8.2%, excluding precious metal content, was led by strong performance in all of the specialty businesses.

 

All Other Regions

 

The internal sales growth of 8.2% in all other regions was primarily the result of continued strong sales growth in Asia (excluding Japan), Middle East/Africa, Canada and Australia.

 

Gross Profit

 

 

 

Three Months Ended  

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(dollars in millions)

 

 

Gross Profit

 

$             268.8

 

$           242.2

 

$          26.6

 

11.0%

Gross Profit as a percentage of net 

 

 

 

 

 

 

 

sales including precious metal content 

53.0%

 

51.3%

 

 

 

 

Gross Profit as a percentage of net 

 

 

 

 

 

 

 

sales excluding precious metal content 

58.2%

 

57.2%

 

 

 

 

 

 

The 1.0% increase from June 30, 2006 to 2007 in the gross profit as a percentage of net sales excluding precious metal content was primarily due to continued favorable product mix and the Company’s lean manufacturing initiatives. Product mix continues to be favorable primarily based on higher growth resulting from Implants and IN-OVATION® C, an interactive bracket system marketed and sold by the Orthodontics business.

 

 

 


Expenses

 

 

 

Three Months Ended  

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(in millions)

 

 

Selling, general and administrative expenses ("SG&A") 

$        172.1

 

$         152.9

 

$          19.2

 

12.5%

Restructuring and other costs, net 

$            3.2

 

$             2.6

 

$            0.6

 

21.7%

 

SG&A Expenses

 

SG&A expenses, measured against sales including precious metal content, increased to 33.9% for the three months ended June 30, 2007 compared to 32.4% for the three months ended June 30, 2006. SG&A expenses, measured against sales excluding precious metal content, increased to 37.2% in 2007 compared to 36.1% in 2006. The increase in the SG&A expenses is primarily a result of our increased sales and marketing expenditures to support growth in the specialty businesses. Currency translation also contributes to the increase in SG&A.

 

Restructuring and Other Costs (Income), Net

 

During the quarter ended June 30, 2007, the Company recorded restructuring and other costs of $3.2 million. The costs associated with the quarter ended June 30, 2007 related to legal settlements and costs related to restructuring.

 

Other Income and Expense

 

 

 

Three Months Ended

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

 

 

(in millions) 

 

Net interest income

 

$           (1.8)

 

$         (0.4)

 

$            (1.4)

Other (income) expense, net

 

(0.3)

 

0.9

 

(1.2)

Net interest and other (income) expense 

$           (2.1)

 

$             0.5

 

$            (2.6)

 

Net Interest Income

 

The increase in net interest income was mainly the result of the continued benefit from the cross currency swaps. Lower average net debt levels in 2007 compared to the prior year period offset by higher interest rates and a weaker U.S. dollar exchange rate versus the Euro and Swiss Franc are other factors that related to the increase in net interest income.

 

Other (Income) Expense, Net

 

Other (income) expense in the 2007 period included approximately $0.4 million of currency transaction gains offset by a decrease in non-operating income of $0.1 million. The 2006 period included $0.6 million of currency transaction losses and $0.3 million of other non-operating losses.

 

Income Taxes and Net Income

 

The Company’s effective tax rate for the three months ended June 30, 2007 increased to 31.6% from 31.1% for the same period in 2006.

 

Net income increased $6.1 million, or 10.3%, to $65.4 million in 2007 from $59.3 million in 2006. Fully diluted earnings per share were $0.42 in 2007, an increase of approximately 13.5% from $0.37 in 2006. Net income in the second quarter of 2007 included restructuring and other costs, net of tax, of $2.0 million, or $0.01 per diluted share, compared to the second quarter of 2006, which included restructuring and other costs, net of tax, of $1.6 million, or $0.01 per diluted share.

 

 

 


Operating Segment Results

 

In January 2007, the Company reorganized its operating group structure expanding into four operating groups from the three groups under the prior management structure. These four operating groups are managed by two Senior Vice Presidents, a Franchise Vice President and an Executive Vice President and represent our operating segments. Each of these operating groups covers a wide range of product categories and geographic regions. The product categories and geographic regions often overlap across the groups. Further information regarding the details of each group is presented in Note 6 of the Unaudited Interim Consolidated Condensed Financial Statements. The management of each group is evaluated for performance and incentive compensation purposes on net third party sales excluding precious metal content and segment operating income.

 

Third Party Net Sales excluding precious metal content

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(dollars in millions)

 

 

U.S., Germany, and Certain Other European 

 

 

 

 

 

 

 

Regions Consumable Businesses

 

$           106.2

 

$      106.7

 

$        (0.5)

 

-0.5%

 

 

 

 

 

 

 

 

 

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

 

$             92.0

 

$        80.4

 

$        11.6

 

14.4%

 

 

 

 

 

 

 

 

 

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

 

Orthodontics

 

$           148.5

 

$      134.5

 

$        14.0

 

10.4%

 

 

 

 

 

 

 

 

 

Global Dental Laboratory Business/

 

 

 

 

 

 

 

 

Implants/Non-Dental

 

$           116.3

 

$      103.1

 

$        13.2

 

12.8%

 

 

Segment Operating Income

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(dollars in millions)

 

 

U.S., Germany, and Certain Other European 

 

 

 

 

 

 

 

Regions Consumable Businesses

 

$               37.9

 

$          40.9

 

$         (3.0)

 

-7.4%

 

 

 

 

 

 

 

 

 

France, U.K., Italy, CIS, Middle East,

 

 

 

 

 

 

 

 

Africa, Pacific Rim Businesses

 

$                 4.1

 

$            2.0

 

$            2.1

 

106.9%

 

 

 

 

 

 

 

 

 

Canada/Latin America/Endodontics/

 

 

 

 

 

 

 

 

Orthodontics

 

$               45.1

 

$          45.0

 

$            0.1

 

0.1%

 

 

 

 

 

 

 

 

 

Global Dental Laboratory Business/

 

 

 

 

 

 

 

 

Implants/Non-Dental

 

$               28.9

 

$          23.9

 

$            5.0

 

20.9%

 

 

United States, Germany, and Certain Other European Regions Consumable Businesses

 

Net sales for this group decreased 0.5% during the three months ended June 30, 2007 compared to 2006. Internal growth was a negative 1.8% offset by positive currency translation of 1.3%. The negative internal growth in this group was primarily a result of reduced promotional activity in Germany and higher first quarter sales in Germany, as additional product was shipped as a result of orders taken during the International Dental Show.

 

Operating profit decreased $3.0 million during the quarter ended June 30, 2007 compared to 2006. The decrease was primarily related to higher expense allocation in the United States and partially offset by the favorable impact of currency translation.

 

 

 


France, United Kingdom, Italy, CIS, Middle East, Africa, Pacific Rim Businesses

 

Net sales for this group increased 14.4% during the three months ended June 30, 2007 compared to 2006. Internal growth was 10.3% with currency translation adding 4.1%. Strong internal growth was shown in the France, CIS, Middle East/Africa, United Kingdom, Asia (excluding Japan) and Australia businesses.

 

Operating profit increased $2.1 million during the quarter ended June 30, 2007 compared to 2006. The increase was primarily related to sales growth, offset somewhat by higher expenses in the Asian and Middle East/Africa businesses. In addition, operating profit was positively impacted from currency translation.

 

Canada/Latin America/Endodontics/Orthodontics

 

Net sales for this group increased 10.4% during the three months ended June 30, 2007 compared to 2006. Internal growth was 8.7% and currency translation added 1.7%. Significant growth was seen in the Orthodontic, Endodontic, and Canadian businesses, partially offset by lower growth in Latin American businesses.

 

Operating profit increased $0.1 million during the quarter ended June 30, 2007 compared to 2006. Increased operating profits in Canada and in the Endodontic business were offset by the decreased operating profits in the Orthodontic business. This group also had a negative impact from exchange due to purchases that were affected by the weakening U.S. dollar.

 

Global Dental Laboratory Business/Implants/Non-Dental

 

Net sales for this group increased 12.8% during the three months ended June 30, 2007 compared to 2006. Internal growth was 8.2% and currency translation added 4.6%. Significant growth was shown in the Implant business and moderate growth in the Global Dental Laboratory business. This was partially offset by negative growth in the Non-Dental businesses.

 

Operating profit increased $5.0 million during the quarter ended June 30, 2007 compared to 2006. The increase in operating profits was driven primarily by the sales growth in the Implant and Global Dental Laboratory businesses and favorable expense management in the Global Dental Laboratory business. In addition, operating profit was positively impacted from currency translation.

 

RESULTS OF CONTINUING OPERATIONS, SIX MONTHS ENDED JUNE 30, 2007 COMPARED TO SIX MONTHS ENDED JUNE 30, 2006

 

Net Sales

 

The following is a reconciliation of net sales to net sales excluding precious metal content.

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(in millions)

 

 

Net sales

 

$          980.2

 

$          903.4

 

$            76.8

 

8.5%

Precious metal content of sales

 

(94.8)

 

(96.5)

 

1.7

 

-1.8%

Net sales excluding precious metal content

$          885.4

 

$          806.9

 

$            78.5

 

9.7%

 

 

The net sales growth of 9.7%, excluding precious metal content, was comprised of 6.3% of internal growth and 3.4% of foreign currency translation. The 6.3% of internal growth was comprised of 4.2% in the United States, 8.3% in Europe and 7.2% for all other regions combined.

 

 

 


Internal Sales Growth

 

 

 

Six Months Ended

 

 

June 30,

 

 

2007

 

2006

United States

 

4.2%

 

3.7%

Europe

 

8.3%

 

9.0%

Other regions

 

7.2%

 

4.1%

 

 

United States

 

The internal sales growth of 4.2%, excluding precious metal content, in the United States was primarily a result of solid growth in Orthodontics and in the dental consumables product categories.

 

Europe

 

In Europe, the internal sales growth of 8.3%, excluding precious metal content, was led by strong performance in all of the specialty businesses.

 

All Other Regions

 

The internal sales growth of 7.2% in all other regions was primarily the result of strong sales growth in Asia (excluding Japan), Middle East/Africa, Canada and Australia.

 

Gross Profit

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

2007

 

2006

 

$ Change

 

% Change

 

 

(dollars in millions)

 

 

Gross Profit

 

$             515.1

 

$           462.3

 

$          52.8

 

11.4%